The Director's Forum series is written and edited by Robert Weber and Michael Sanborn and is designed to guide pharmacy leaders in establishing patient-centered services in hospitals and health systems. Another specific goal of this column is to address many of the key challenges that pharmacy directors face today, while providing information to foster growth in pharmacy leadership and patient safety. This month's Forum is co-authored by Scott Mark and focuses directly on processes for determining program priorities for patient safety and implementing a successful program.
Get full access to this article
View all access options for this article.
References
1.
BatesD.W., CullenD.J., LairdN.. Incidence of adverse drug events and potential adverse drug events: implications for prevention, ADE Prevention Study Group. JAMA.1995; 274: 29–34.
2.
McDermottR., MikulakR., BeauregardM.The Basics of FMEA.New York, New York: Productivity Press;1996; 3.
3.
CohenM.R., SendersJ., DavisN.M.Failure mode and effects analysis: a novel approach to avoiding dangerous medication errors and accidents. Hosp Pharm.1994; 29: 319–324,326-328,330.
4.
WilliamsE., TalleyR.The use of failure mode effect and criticality analysis in a medication error subcommittee. Hosp Pharm.1994; 29: 331–332, 334-339.
5.
DerosierJ., StalhandskeE., BaglanJ.P., NudellT.Using health care failure mode and effect analysis: the VA National Center for Patient Safety's Prospective Risk Analysis System. JCAHO J Qual Improv.2002; 28: 254.
